Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
Authors
Keywords
-
Journal
EBioMedicine
Volume 73, Issue -, Pages 103679
Publisher
Elsevier BV
Online
2021-11-08
DOI
10.1016/j.ebiom.2021.103679
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- COVID‐19 infection in solid organ transplant recipients after SARS‐CoV‐2 vaccination
- (2021) Hani M. Wadei et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
- (2021) Brian J. Boyarsky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
- (2021) Brian J. Boyarsky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- (2021) Eric J Haas et al. LANCET
- Cellular and humoral response after MRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients
- (2021) David Cucchiari et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
- (2021) William A. Werbel et al. ANNALS OF INTERNAL MEDICINE
- Occurrence of severe COVID-19 in vaccinated transplant patients
- (2021) Sophie Caillard et al. KIDNEY INTERNATIONAL
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
- (2021) Nassim Kamar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
- (2021) Johan Normark et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study
- (2020) David Liebowitz et al. LANCET INFECTIOUS DISEASES
- Factors associated with COVID-19-related death using OpenSAFELY
- (2020) Elizabeth J. Williamson et al. NATURE
- Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?
- (2020) John S. Tsang et al. TRENDS IN IMMUNOLOGY
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania
- (2019) Zacchaeus Anywaine et al. JOURNAL OF INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started